Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects

Trial Profile

A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs BBT 877 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Bridge Biotherapeutics
  • Most Recent Events

    • 02 Feb 2019 Status changed from planning to recruiting.
    • 16 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019, according to a Bridge Biotherapeutics media release.
    • 16 Jan 2019 According to a Bridge Biotherapeutics media release, this study will begin next month.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top